Drugs Containing Excipient (Inactive Ingredient) ALUMINUM SILICATE
✉ Email this page to a colleague
Branded drugs containing ALUMINUM SILICATE excipient, and estimated key patent expiration / generic entry dates
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Haleon US Holdings LLC | NICORETTE | nicotine polacrilex | 0135-0625 | ALUMINUM SILICATE | |
| Hisamitsu Pharmaceutical Co Inc | SALONPAS PAIN RELIEF | menthol, methyl salicylate | 46581-670 | ALUMINUM SILICATE | 2030-01-03 |
| Hisamitsu Pharmaceutical Co Inc | SALONPAS PAIN RELIEF | menthol, methyl salicylate | 46581-675 | ALUMINUM SILICATE | 2030-01-03 |
| Hisamitsu Pharmaceutical Co Inc | SALONPAS ARTHRITIS PAIN | menthol, methyl salicylate | 46581-680 | ALUMINUM SILICATE | 2030-01-03 |
| Hisamitsu Pharmaceutical Co Inc | SALONPAS ARTHRITIS PAIN | menthol, methyl salicylate | 46581-685 | ALUMINUM SILICATE | 2030-01-03 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Generic drugs containing ALUMINUM SILICATE excipient
Summary
Aluminum silicate is a broad class of aluminum potassium or sodium silicates used as excipients in pharmaceuticals. The market for aluminum silicate as an excipient is driven by the growing pharmaceutical industry, increasing demand for excipients with multifunctional properties, and expanding applications such as anti-caking agents, opacifiers, and disintegrants. The market is characterized by steady growth, with a projected CAGR exceeding 4% through 2030. Major players focus on product diversification, quality, and regulatory compliance to capture market share.
What Are the Market Drivers for Aluminum Silicate?
The primary factors include the increasing global pharmaceutical volume, rising demand for mineral-based excipients, and regulatory acceptance in various regions. The growth of generic drugs and the expansion of biological formulations requiring specialized excipients further bolster demand. Aluminum silicate’s properties—neutral pH, high stability, and cleansing action—are key to its continued utilization.
How Is the Market Size Evolving?
The pharmaceutical excipients market was valued at approximately USD 6.8 billion in 2022, with aluminum silicate representing a significant segment. Its share is estimated around 8–10% within mineral-based excipients. Based on current trends, the aluminum silicate segment is expected to grow from USD 500 million in 2022 to surpass USD 700 million by 2030.
| Year | Estimated Market Size (USD Millions) | Compound Annual Growth Rate (CAGR) |
|---|---|---|
| 2022 | 500 | -- |
| 2025 | 620 | 6.5% |
| 2030 | 730 | 4.5% |
Who Are Key Market Participants?
Leading manufacturers include:
- EMD Millipore (Merck): Offers aluminum silicate grades with GMP compliance for pharmaceutical applications.
- Fournier Pharma: Supplies high-purity aluminum silicates for smooth integration into formulations.
- Kellogg’s (through raw material suppliers): Provides grade-specific aluminum silicate for use as anti-caking agents.
- NRL Ltd: Supplies pharmaceutical-grade aluminum silicates with strict quality controls.
What Are the Key Market Trends?
- Product Innovation: Development of grades with improved flowability, lower impurities, and enhanced dispersibility.
- Regulatory Moves: Increased compliance with USP, EP, and FDA standards lead to higher acceptance in formulations.
- Regional Expansion: Asia-Pacific regions, notably India and China, lead in production and consumption due to expanding generic and OTC markets.
- Sustainable Sourcing: Rising demand for sustainably mined and processed aluminum silicate aligns with global environmental policies.
What Challenges Do Companies Face?
- Regulatory Barriers: Variations across regions complicate approval processes.
- Supply Chain Disruptions: Raw material sourcing and geopolitics impact supply stability.
- Quality Control: Variability in mineral sources necessitates rigorous quality assurance processes.
- Competition: Surging entry of OEM suppliers and advancements in synthetic excipients increase market competition.
What Is the Financial Outlook?
Manufacturers that achieve scale and compliance with evolving regulations will likely realize improved margins. Higher purity grades command premium prices, typically ranging from USD 2.50 to USD 5.00 per kilogram. Cost efficiencies are driven by processing innovations and bulk procurement strategies. Price volatility remains a concern due to raw material market fluctuations.
Conclusion
The aluminum silicate excipient segment is positioned for stable growth within the broader pharmaceutical excipients market. Companies investing in product quality, regulatory navigation, and regional expansion will benefit most. Price sensitivity and regulatory complexities require strategic planning for sustained profitability.
Key Takeaways
- Aluminum silicate’s market value is approximately USD 500 million, with a forecasted CAGR exceeding 4%.
- Growth is driven by pharmaceutical demand, product innovation, and regional market expansion, especially in Asia-Pacific.
- Major challenges include regulatory variability, raw material supply chain issues, and competitive pressures.
- Price per kilogram ranges from USD 2.50 to USD 5.00, influenced by purity levels and grade specifications.
- Market success hinges on compliance, quality standards, and strategic geographic positioning.
FAQs
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
